menu
    • menu
    [{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Canada Royal Enoch Phytomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Ginsenoside","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canada Royal Enoch Phytomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Canada Royal Enoch Phytomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Canada Royal Enoch Phytomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ University Of Alabama","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ University Of Alabama"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"VEGF receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Iodide","moa":"ROS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Faraday Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Faraday Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Galen Patient Recruitment","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Galen Patient Recruitment","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Galen Patient Recruitment"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SL-1002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ PRC Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ PRC Clinical"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SL-1002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Garetosmab","moa":"Activin A","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Undisclosed"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MIV-711","moa":"Cathepsin-K","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"||NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Novotech"},{"orgOrder":0,"company":"Genascence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Inapplicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Inapplicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Pacira BioSciences"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||ANGPTL3","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Levicept","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"LEVI-04","moa":"Neurotrophin pathway","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Levicept","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Levicept \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Levicept \/ Inapplicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mestex AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Mestex AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Mestex AG \/ Grunenthal","highestDevelopmentStatusID":"8","companyTruncated":"Mestex AG \/ Grunenthal"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"XT-150","moa":"IL-10 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Xalud Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ PBM Capital"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series C Financing","leadProduct":"AGA2118","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGA2118","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Oxford Finance"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"PharmaCyte Biotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ PharmaCyte Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ PharmaCyte Biotech"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Renova Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Renova Health","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Renova Health"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Aegis Capital","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Aegis Capital"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Aegis Capital","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Aegis Capital"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ PPD"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Renova Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Renova Health","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Renova Health"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Dentonin","moa":"Integrin","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avicanna \/ University Health Network","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ University Health Network"}]

    Find Musculoskeletal Drugs in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avicanna

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : University Health Network

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain

                            Details : The primary objective of the RCT is to evaluate oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            May 20, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : University Health Network

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OrthoTrophix

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            OrthoTrophix

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dentonin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OrthoTrophix Starts Phase 2b TPX-100 Trial for Knee Osteoarthritis Patients

                            Details : TPX-100 is being developed as a potential disease-modifying osteoarthritis drug (DMOAD), a class of therapies that aim not only to alleviate symptoms but to slow or halt disease progression.

                            Product Name : TPX-100

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : Dentonin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TNF Pharmaceuticals

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            TNF Pharmaceuticals

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Renova Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TNF & Renova Show Targeting Potential for Inflammation with GLP-1 Therapy

                            Details : The study series is expected to evaluate the impact of the Company’s novel oral TNF-alpha inhibitor, MYMD-1 (isomyosamine), in preserving lean muscle mass during and after GLP-1 treatment.

                            Product Name : MYMD-1

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 08, 2025

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Renova Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pacira BioSciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Pacira BioSciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enekinragene Inzadenovec

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pacira to Present 104-Week Data on PCRX-201 in Knee Osteoarthritis

                            Details : PCRX-201 (enekinragene inzadenovec) is an IL-1 receptor inhibitor gene therapy candidate, which is currently being evaluated for the treatment of osteoarthritis of the knee.

                            Product Name : PCRX-201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : Enekinragene Inzadenovec

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pacira BioSciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            Pacira BioSciences

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enekinragene Inzadenovec

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pacira Doses First Patient in Phase 2 Study of PCRX-201 for Knee Osteoarthritis

                            Details : Pacira’s novel product candidate PCRX-201 (enekinragene inzadenovec), features an innovative design based on the company’s proprietary high-capacity adenovirus vector platform.

                            Product Name : PCRX-201

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : Enekinragene Inzadenovec

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            4Moving Biotech

                            France arrow
                            Pharmex
                            Not Confirmed

                            4Moving Biotech

                            France arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            4Moving Biotech Starts Phase 2a Knee Osteoarthritis Trial in Canada

                            Details : 4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti-catabolic, and anabolic benefits of GLP-1.

                            Product Name : 4P004

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 27, 2025

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Antibe Therapeutics

                            Canada arrow
                            Pharmex
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sun Pharma Subsidiary Taro Acquires Antibe Therapeutics

                            Details : Through the acquisition, Taro will leverage Antibe pipeline, including ATB-346 (otenaproxesul), a novel NSAID. It is being evaluated for the treatment of Osteoarthritis.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 16, 2025

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TNF Pharmaceuticals

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            TNF Pharmaceuticals

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

                            Details : MYMD-1 (isomyosamine) is a TNF-alpha inhibitor drug, currently being investigated in patients with sarcopenia/frailty.

                            Product Name : MYMD-1

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AEON Biopharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            AEON Biopharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prabotulinumtoxin A

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Aegis Capital

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

                            Details : The net proceeds will be used to advance the clinical development of company's lead product ABP-450 (Prabotulinumtoxin A). It is being evaluated for the treatment of Cervical dystonia.

                            Product Name : ABP-450

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Prabotulinumtoxin A

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Aegis Capital

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AEON Biopharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed

                            AEON Biopharma

                            U.S.A arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prabotulinumtoxin A

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Aegis Capital

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            AEON Biopharma Announces $20M Underwritten Public Offering Pricing

                            Details : The net proceeds will be used to advance the clinical development of company's lead product ABP-450 (Prabotulinumtoxin A). It is being evaluated for the treatment of Cervical dystonia.

                            Product Name : ABP-450

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Prabotulinumtoxin A

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Aegis Capital

                            Deal Size : $20.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth